Altogether, the work presented here not only describes the role of two DNA repair factors in controlling DNA repair pathway choice, but it also provides the first evidence that SHLD2 could benefit clinicians as a relevant biomarker for a subset of BC. The gene discussed is SHLD2; the disease is breast cancer.